Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 5
Submit an article Journal homepage
794
Views
41
CrossRef citations to date
0
Altmetric
Review

Drug safety and tolerability in prophylactic migraine treatment

László VécseiUniversity of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary+36 62 545348; +36 62 545597; [email protected];University of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary;MTA – SZTE Neuroscience Research Group, Semmelweis u. 6, H-6725 Szeged, Hungary
, MD PhD DSc (Member of the Hungarian Academy of Sciences) ,
Zsófia MajláthUniversity of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary
, MD (Resident in Clinical Neurology) ,
Délia SzokUniversity of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary
, MD PhD (Associate Professor of Clinical Neurology) ,
Anett CsátiUniversity of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary
, MD PhD (Resident in Clinical Neurology) &
János TajtiUniversity of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary
, MD PhD (Associate Professor of Clinical Neurology) (Head of the Department of Neurology) (Associate Professor of Clinical Neurology) (Head of the Department of Neurology)
Pages 667-681 | Published online: 13 Feb 2015

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Hisaka Igarashi, Mamoru Shibata, Akichika Ozeki, Kathleen Ann Day & Taka Matsumura. (2021) Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine. Journal of Pain Research 14, pages 3555-3564.
Read now
Paolo Martelletti, Michelangelo Luciani, Valerio Spuntarelli & Enrico Bentivegna. (2021) Deprescribing in migraine. Expert Opinion on Drug Safety 20:6, pages 623-625.
Read now
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Yoshihisa Tatsuoka, Norihiro Suzuki, Hisaka Igarashi, Tomomi Nakamura, Akichika Ozeki, Hiroyoshi Yamazaki & Vladimir Skljarevski. (2021) A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opinion on Drug Safety 20:6, pages 721-733.
Read now
János Tajti, Délia Szok, Aliz Nyári & László Vécsei. (2019) Therapeutic strategies that act on the peripheral nervous system in primary headache disorders. Expert Review of Neurotherapeutics 19:6, pages 509-533.
Read now
László Vécsei, Délia Szok, Aliz Nyári & János Tajti. (2018) Treating status migrainosus in the emergency setting: what is the best strategy?. Expert Opinion on Pharmacotherapy 19:14, pages 1523-1531.
Read now

Articles from other publishers (36)

Mamoru Shibata, Atsuko Nihira, Yuka Tanji, Akichika Ozeki, Hideyuki Imagawa & Mika Komori. (2023) Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial. Neurology and Therapy 12:6, pages 2007-2019.
Crossref
Leon S. Moskatel & Niushen Zhang. (2023) The Role of Step Therapy in the Treatment of Migraine. Current Pain and Headache Reports.
Crossref
Maria E. CasariChristian ChartierLisa GfrererWilliam G. Austen. (2022) Evidence-Based Patient Selection in Headache Surgery: Impact of Preoperative Radiofrequency Ablation on Surgical Outcomes. Plastic & Reconstructive Surgery 151:5, pages 1071-1077.
Crossref
Mahsa Bagherzadeh-Fard, Mohammad Amin Yazdanifar, Mona Sadeghalvad & Nima Rezaei. (2023) Erenumab efficacy in migraine headache prophylaxis: A systematic review. International Immunopharmacology 117, pages 109366.
Crossref
Délia Szok, Anett Csáti, László Vécsei & János Tajti. (2023) Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review. Life 13:3, pages 665.
Crossref
Marcello Silvestro, Alessandro Tessitore, Ilaria Orologio, Rosa De Micco, Lorenzo Tartaglione, Francesca Trojsi, Gioacchino Tedeschi & Antonio Russo. (2022) Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. The Journal of Headache and Pain 23:1.
Crossref
Peng Zhao, Ningyan Zhang & Zhiqiang An. (2022) Engineering antibody and protein therapeutics to cross the blood–brain barrier. Antibody Therapeutics 5:4, pages 311-331.
Crossref
Simona Lattanzi, Eugen Trinka, Claudia Altamura, Cinzia Del Giovane, Mauro Silvestrini, Francesco Brigo & Fabrizio Vernieri. (2022) Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety. Neurology and Therapy 11:3, pages 1235-1252.
Crossref
Shaohua Lyu, Claire Shuiqing Zhang, Xinfeng Guo, Anthony Lin Zhang, Jingbo Sun, Genghang Chen, Charlie Changli Xue & Xiaodong Luo. (2022) Efficacy and Safety of Oral Chinese Herbal Medicine for Migraine: A Systematic Review and Meta-Analyses Using Robust Variance Estimation Model. Frontiers in Neurology 13.
Crossref
János Tajti, Délia Szok, Aliz Nyári & László Vécsei. (2022) CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021. CNS & Neurological Disorders - Drug Targets 21:6, pages 460-478.
Crossref
Fenne Vandervorst, Laura Van Deun, Annelies Van Dycke, Koen Paemeleire, Uwe Reuter, Jean Schoenen & Jan Versijpt. (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. The Journal of Headache and Pain 22:1.
Crossref
Ariane K. Kawata, Neel Shah, Jiat‐Ling Poon, Shannon Shaffer, Sandhya Sapra, Teresa K. Wilcox, Shweta Shah, Stewart J. Tepper, David W. Dodick & Richard B. Lipton. (2021) Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache: The Journal of Head and Face Pain 61:3, pages 438-454.
Crossref
Ruifang Yuan, Dingkun Zhang, Jinhui Yang, Zhenfeng Wu, Chuanhong Luo, Li Han, Fangli Yang, Junzhi Lin & Ming Yang. (2021) Review of aromatherapy essential oils and their mechanism of action against migraines. Journal of Ethnopharmacology 265, pages 113326.
Crossref
Shaohua Lyu, Claire Shuiqing Zhang, Xinfeng Guo, Anthony Lin Zhang, Jingbo Sun, Chuanjian Lu, Charlie Changli Xue & Xiaodong Luo. (2020) Oral Chinese Herbal Medicine as Prophylactic Treatment for Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine 2020, pages 1-20.
Crossref
Afrim Iljazi, Håkan Ashina, Richard B Lipton, Basit Chaudhry, Haidar M Al-Khazali, James G Naples, Henrik W Schytz, Vlasta Vukovic Cvetkovic, Rami Burstein & Sait Ashina. (2020) Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis. Cephalalgia 40:10, pages 1095-1103.
Crossref
Peter J. Goadsby, Uwe ReuterYngve HallströmGregor BroessnerJo H. BonnerFeng ZhangIan K. WrightDenise E. ChouJan KlattHernan PicardRobert A. LenzDaniel D. Mikol. (2020) One-year sustained efficacy of erenumab in episodic migraine. Neurology 95:5.
Crossref
Yushuang Deng, Min Zheng, Lanying He, Juan Yang, Gang Yu & Jian Wang. (2020) A Head-to-Head Comparison of Percutaneous Mastoid Electrical Stimulator and Supraorbital Transcutaneous Stimulator in the Prevention of Migraine: A Prospective, Randomized Controlled Study. Neuromodulation: Technology at the Neural Interface 23:6, pages 770-777.
Crossref
Victor Carramiñana, Ana M. Ochoa de Retana, Francisco Palacios & Jesús M. de los Santos. (2020) Synthesis of α-Aminophosphonic Acid Derivatives Through the Addition of O- and S-Nucleophiles to 2H-Azirines and Their Antiproliferative Effect on A549 Human Lung Adenocarcinoma Cells. Molecules 25:15, pages 3332.
Crossref
Shengyuan Yu, Ye Ran, Wei Xiao, Wenjing Tang, Jianjun Zhao, Wei Chen, Huikui Zhuang, Cun Ouyang, Hai Lin, Dequan Liu, Tongjun Chen, Hui Huang, Baoshen Wang, Yanlei Hao, Zhongrui Yan, Shike Zhao, Yanling Wang, Jinjun Ni, Chaodong Wang, Wentao Ding, Guoqian Li, Jianhua Cao & Shujuan Tian. (2019) Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial. BMC Complementary and Alternative Medicine 19:1.
Crossref
Anker Stubberud, Nikolai Melseth Flaaen, Douglas C. McCrory, Sindre Andre Pedersen & Mattias Linde. (2019) Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. BÓL 20:1, pages 25-38.
Crossref
Anker Stubberud, Nikolai Melseth Flaaen, Douglas C. McCrorySindre Andre Pedersen & Mattias Linde. (2018) Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 160:4, pages 762-772.
Crossref
Simona Lattanzi, Francesco Brigo, Eugen Trinka, Fabrizio Vernieri, Tommaso Corradetti, Mauro Dobran & Mauro Silvestrini. (2019) Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. Drugs 79:4, pages 417-431.
Crossref
Li Jiang, Dong Li Yuan, Maolin Li, Chaoyang Liu, Qing Liu, Yixin Zhang & Ge Tan. (2018) Combination of flunarizine and transcutaneous supraorbital neurostimulation improves migraine prophylaxis. Acta Neurologica Scandinavica.
Crossref
Uwe Reuter. (2018) A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine. Headache: The Journal of Head and Face Pain 58, pages 48-59.
Crossref
Heike Israel, Lars Neeb & Uwe Reuter. (2018) CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. Current Pain and Headache Reports 22:5.
Crossref
Michele Romoli, Cinzia Costa, Sabrina Siliquini, Ilenia Corbelli, Paolo Eusebi, Chiara Bedetti, Stefano Caproni, Letizia Maria Cupini, Paolo Calabresi & Paola Sarchielli. (2016) Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. Cephalalgia 38:2, pages 274-282.
Crossref
Yang Juan, Ou Shu, Lou Jinhe, Yang Na, Deng Yushuang, Dong Weiwei, He Lanying & Wang Jian. (2016) Migraine prevention with percutaneous mastoid electrical stimulator: A randomized double-blind controlled trial. Cephalalgia 37:13, pages 1248-1256.
Crossref
Ferda Ince, Emel Erdogan-Bakar & Isin Unal-Cevik. (2017) Preventive drugs restore visual evoked habituation and attention in migraineurs. Acta Neurologica Belgica 117:2, pages 523-530.
Crossref
Peiwei Hong, Xintong Wu & Yao Liu. (2017) Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. Clinical Neurology and Neurosurgery 154, pages 74-78.
Crossref
Federico Castillo-Álvarez, Ignacio Hernando de la Bárcena & María Eugenia Marzo-Sola. (2017) Toxina botulínica en la neuralgia del trigémino. Medicina Clínica 148:1, pages 28-32.
Crossref
Federico Castillo-Álvarez, Ignacio Hernando de la Bárcena & María Eugenia Marzo-Sola. (2017) Botulinum toxin in trigeminal neuralgia. Medicina Clínica (English Edition) 148:1, pages 28-32.
Crossref
Juliana VanderPluym, Randolph W. Evans & Amaal J. Starling. (2016) Long-Term Use and Safety of Migraine Preventive Medications. Headache: The Journal of Head and Face Pain 56:8, pages 1335-1343.
Crossref
Faraidoon Haghdoost. (2016) Is There an Inverse Relationship Between Migraine and Dietary Sodium Intake?. Headache: The Journal of Head and Face Pain 56:7, pages 1212-1213.
Crossref
Hong Sun, David W Dodick, Stephen Silberstein, Peter J Goadsby, Uwe Reuter, Messoud Ashina, Joel Saper, Roger Cady, Yun Chon, Julie Dietrich & Robert Lenz. (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology 15:4, pages 382-390.
Crossref
János Tajti, Délia Szok, Anett Csáti & László Vécsei. (2015) Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update. Current Pain and Headache Reports 20:1.
Crossref
Délia Szok, Anett Csáti, László Vécsei & János Tajti. (2015) Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. Toxins 7:7, pages 2659-2673.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.